All sponsors

Beijing Biotech

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS28
PHASE 3 / 2-30
RECRUITING28
READOUTS ≤12 MONTHS27
Open Beijing Biotech on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
DUO-NK-NSCLC
NCT07467863
P1/2RecruitingNon-Small Cell Lung Cancer; Advanced/Metastatic NSCLC482027-02-14
SOLID-NK
NCT07589530
P1/2RecruitingAdvanced Solid Tumors; Metastatic Solid Tumors602027-02-14
DUAL-NK-BC
NCT07486089
P1/2RecruitingBreast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer602027-02-14
DUAL-NK-PDAC
NCT07480928
P1/2RecruitingPancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease422027-02-14
EB-DART-NK01
NCT07744256
P1/2RecruitingSmall Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC602027-02-14
DART-NK-SCLC
NCT07480213
P1/2RecruitingSmall Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC602027-02-14
DUAL-OV-CAR-NK
NCT07480954
P1/2RecruitingEpithelial Ovarian Cancer; Primary Peritoneal Carcinoma362027-02-17
EB-DUALNK-OV
NCT07589543
P1/2RecruitingEpithelial Ovarian Cancer; Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum422027-03-14
DUET-BTC
NCT07641036
P1/2RecruitingCholangiocarcinoma; Intrahepatic Cholangiocarcinoma302027-03-14
EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells
NCT07622940
P1/2RecruitingRecurrent or Metastatic Esophageal Adenocarcinoma; Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease362027-03-14
Dual-target CAR-NK cells
NCT07510802
P1/2RecruitingBreast Cancer (Advanced/Metastatic); HER2-positive Breast Cancer602027-03-14
DUO-NK-NSCLC
NCT07641023
P1/2RecruitingNon-Small Cell Lung Cancer; Advanced/Metastatic602027-03-14
DUET-GEJ
NCT07551362
P1/2RecruitingAdvanced Gastric Adenocarcinoma; Advanced Gastroesophageal Junction Adenocarcinoma362027-03-14
DUO-CRC-NK-111
NCT07589517
P1/2RecruitingColorectal Cancer; Metastatic Colorectal Adenocarcinoma482027-03-14
DUAL-MESO-NK
NCT07510815
P1/2RecruitingMalignant Pleural Mesotheliomas362027-03-14
DUET-HCC
NCT07500220
P1/2RecruitingAdvanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer302027-03-14
SELECT-SLE
NCT07523542
P1/2RecruitingREFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS; Lupus Nephritis242027-03-14
DUAL-NK-NB
NCT07502287
P1/2RecruitingRelapsed Neuroblastoma; Refractory Neuroblastoma362027-03-14
PRISM-NK
NCT07510828
P1/2RecruitingAdvanced or Metastatic Solid Tumors602027-03-14
ADAPT-HEM
NCT07523555
P1/2RecruitingRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL962027-03-14
DUAL-HN
NCT07617805
P1/2RecruitingRecurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC422027-03-14
DUAL-NK-PDAC
NCT07627711
P1/2RecruitingPancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced422027-04-14
SELECT-2CAR
NCT07523529
P1/2RecruitingAdvanced Unresectable; Metastatic722027-04-14
DUAL-NK RCC
NCT07551349
P1/2RecruitingAdvanced or Metastatic Clear Cell Renal Cell Carcinoma362027-04-14
DUAL-OV-CAR-NK
NCT07617753
P1/2RecruitingEpithelial Ovarian Cancer; Primary Peritoneal Carcinoma362027-06-14
SELECT-NK-THYM
NCT07598955
P1/2RecruitingB2 Thymoma; Thymic Carcinoma362027-06-14
DUET-MEL
NCT07627698
P1/2RecruitingUnresectable Melanoma; Metastatic Cutaneous Melanoma362027-06-14
EB-DUO-CAR-NK-CEA/GCC (IV)
NCT07462650
P1/2RecruitingColorectal Cancer Metastatic; Adenocarcinoma of Colon482027-12-21